CA
NZ
UK
AU
IND
US
Q2 Revenue Growth Led by HIV Products
GSK plc (LSE: GSK), a leading drug manufacturer with a marketCapitalizationof approximately $76.9 billion, has achieved regulatory approval for a chronic hepatitis B drug and a cancer therapy aimed at solid tumors. This move comes at a time when the company seeks to expand …
Inovio is on the verge of a critical decision from the FDA, which is poised to impact its future significantly within the biopharmaceutical environment. The FDA's judgment will potentially confirm the company's development progress and could directly affect its stock market performance. Investors are …
Zoetis Expands TreatmentOptionswith Simparica Trio
UPS is committing $2 billion to elevate its international and healthcare operations, a move seen as important in enhancing the company’s logistics capabilities. This investment underscores UPS's strategy to adapt to increasing demand for faster and more resilient supply chains. By enhancing its infrastructure …
Biogen is experiencing renewed investor attention following RBC Capital's recent upgrade of its price target based on the promising potential of its lupus drug pipeline. Analysts have noted that this move aligns with an overall positive outlook for autoimmune therapies, which have garnered increasing …
Earnings Highlights and Growth Strategy
Aveanna Healthcare Holdings, Inc. has executed a secondary offering involving 15 million shares of its common stock, priced at $11.75 per share. This strategic move allows existing shareholders to sell their shares while the company itself will not benefit from any proceeds, as it …
BioCardia, Inc. (NASDAQ: BCDA) has received confirmation from the FDA regarding the meeting minutes pertaining to the Helix Transendocardial Delivery Catheter System, following the recent FDA pre-submission meeting. This confirmation, released on August 24, 2026, solidifies the company's previous communications with the agency, including …
The outcome highlights both the risks of ongoing litigation and Cytek Biosciences, Inc. (NASDAQ: CTKB)'s ability to defend its intellectual property amidst complex legal challenges.
Please wait processing your request...